Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 12/20 | 0.59 |
| ▸ | MAOB | P27338 | 12/20 | 0.59 |
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315147 | 0.96 | MAOA (0.61) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL16082766 | 0.88 | CASP1 (0.59) | MAOAMAOBPRKCIHSD17B1GRM5 | |
| SCHEMBL12500758 | 0.84 | MAOA (0.48) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL3665755 | 0.80 | MAOA (0.53) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL26638890 | 0.77 | TDP2 (0.58) | MAOAMAOBPRKCICASP1CASP7 | |
| SCHEMBL13193777 | 0.76 | PNMT (0.52) | MAOAMAOBHSD17B10TDP2MEN1 | |
| SCHEMBL3204625 | 0.76 | CASP1 (0.78) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL5108894 | 0.76 | MAOA (0.61) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL3825921 | 0.76 | MAOA (0.92) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL29521431 | 0.76 | MAOA (0.59) | MAOAMAOBPRKCIHSD17B1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746064-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE BRAIN INJURY | UNIV COPENHAGEN (DK) | 2025-04-16 | — | — | EP | disclosed |
| US-20240391865-A1 | COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY | OTAGO INNOVATION LIMITED (NZ) | 2024-11-28 | — | — | US | disclosed |
| US-12077495-B2 | Compounds for the treatment of acute brain injury | Københavns Universitet (DK) | 2024-09-03 | — | — | US | disclosed |
| US-20210122700-A1 | COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY | UNIVERSITY OF OTAGO (NZ) | 2021-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077495-B2 | Compounds for the treatment of acute brain injury | F2R, F2RL3, ARG2 | MAOA 925/4885MAOB 620/4885PRKCI 3411/4885 |
| US-20210122700-A1 | COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY | F2R, F2RL3, ARG2 | MAOA 922/4885MAOB 654/4885PRKCI 3384/4885 |
| US-20240391865-A1 | COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY | F2R, F2RL3, ARG2 | MAOA 922/4885MAOB 654/4885PRKCI 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.